Jon Schultz, who monitors a number of 'disease domains' from his home in Las Vegas, bought Ebola.com in 2008 and now believes he can sell it for $150,000. The businessman also owns birdflu.com and H1N1.com, as well a domain for the deadly mosquito-borne disease Chikungunya and another for the Ebola-like Marburg virus. He paid $13,500 for his Ebola domain four years ago and has been waiting for the moment to sell.
'Ebola.com would be a great domain for a pharmaceutical company working on a vaccine or cure, a company selling pandemic or disaster-preparedness supplies, or a medical company wishing to provide information and advertise services,' Mr Schultz told CNBC in an emailed statement.
'There could be many other applications as well. With so many people concerned about the disease, any advertisement referring people to Ebola.com should get an excellent response.'
In an interview with the Washington Post, Mr Schultz said he felt that a six figure sum was more than reasonable for Ebola.com. 'According to our site meter, we're already doing 5,000 page views per day just by people typing in Ebola.com to see what's there,' he said.
'We're getting inquiries every day about the sale of it. I have a lot of experience in this sort of domain business, and my sense is that $150,000 is reasonable.'
Mr Schultz, who also owns terror.com, PotassiumIodide.com and fukushima.com, appeared untroubled about the issue of making money from a human tragedy.
Mr Schultz told the Washington Post he wants to sell the domain soon because he is worried something may 'ameliorate' the outbreak, diminishing Ebola's news value and the value of the domain. 'Ebola is either something that could become more of a problem, or it's something that could ameliorate and not be a big news story for that much longer,' he said. But the entrepreneur still has other domain's to fall back on should Ebola.com lose its value.
'Our domain, birdflu.com, is worth way more than Ebola.com. We're definitely holding onto that one for the event,' he said, referring to an outbreak he believes could be far bigger than Ebola. 'That one's airborne and Ebola would never go airborne in the United States like bird flu can.'
Credits: Washington Post / DailyMail / CNBC
'Ebola.com would be a great domain for a pharmaceutical company working on a vaccine or cure, a company selling pandemic or disaster-preparedness supplies, or a medical company wishing to provide information and advertise services,' Mr Schultz told CNBC in an emailed statement.
'There could be many other applications as well. With so many people concerned about the disease, any advertisement referring people to Ebola.com should get an excellent response.'
In an interview with the Washington Post, Mr Schultz said he felt that a six figure sum was more than reasonable for Ebola.com. 'According to our site meter, we're already doing 5,000 page views per day just by people typing in Ebola.com to see what's there,' he said.
'We're getting inquiries every day about the sale of it. I have a lot of experience in this sort of domain business, and my sense is that $150,000 is reasonable.'
Mr Schultz, who also owns terror.com, PotassiumIodide.com and fukushima.com, appeared untroubled about the issue of making money from a human tragedy.
Mr Schultz told the Washington Post he wants to sell the domain soon because he is worried something may 'ameliorate' the outbreak, diminishing Ebola's news value and the value of the domain. 'Ebola is either something that could become more of a problem, or it's something that could ameliorate and not be a big news story for that much longer,' he said. But the entrepreneur still has other domain's to fall back on should Ebola.com lose its value.
'Our domain, birdflu.com, is worth way more than Ebola.com. We're definitely holding onto that one for the event,' he said, referring to an outbreak he believes could be far bigger than Ebola. 'That one's airborne and Ebola would never go airborne in the United States like bird flu can.'
Credits: Washington Post / DailyMail / CNBC
No comments:
Post a Comment